EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome

Abram Bunya Kamiza, Wen Chang Wang, Jeng Fu You, Reiping Tang, Yen Ting Wang, Huei Tzu Chien, Chih Hsiung Lai, Li Ling Chiu, Tsai Ping Lo, Kuan Yi Hung, Chao Agnes Hsiung, Chih Ching Yeh

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: Epidermal growth factor receptor (EGFR), mothers against decapentaplegic homolog 7 (SMAD7) and transforming growth factor betta (TGFB) are crucial for colorectal cancer (CRC) tumorigenesis. This study investigated whether polymorphisms in EGFR, SMAD7, and TGFB are associated with CRC risk in patients with Lynch syndrome. Materials and Methods: Genotyping was performed using Sequenom iPLEX MassArray. Association between genetic polymorphisms and CRC was assessed using a weighted Cox proportional hazard model. Results: Patients carrying the AA genotype of EGFR rs2227983 had a significantly higher CRC risk than those carrying the G allele (HR=2.55, 95% CI=1.25-5.17). The dominant model of SMAD7 rs12953717 (CT + TT genotypes) significantly increased CRC risk (HR=2.17, 95% CI=1.12-4.16) when compared to the wild-type CC genotype. Similarly, the GG genotype of TGFBR2 rs6785358 significantly increased the risk of CRC (HR=21.1, 95% CI=5.06-88.1) compared to the AA genotype. Conclusion: EGFR, SMAD7, and TGFBR2 are associated with CRC risk in patients with Lynch syndrome.

Original languageEnglish
Pages (from-to)5983-5990
Number of pages8
JournalAnticancer Research
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 1 2018

Keywords

  • Colorectal cancer
  • CRC risk
  • EGFR
  • Lynch syndrome
  • Polymorphisms
  • SMAD7
  • TGFB

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'EGFR, SMAD7, and TGFBR2 polymorphisms are associated with colorectal cancer in patients with lynch syndrome'. Together they form a unique fingerprint.

Cite this